id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-325432-geb4esu5	Bukreyeva, Natalya	The IMPDH inhibitor merimepodib suppresses SARS-CoV-2 replication in vitro	2020-04-09		.txt	text/plain	1036	65	49	Drugs with history of being tested in human patients or used for treatment of other conditions offer the most expedient option, and several such drugs are currently being tested for efficacy against SARS-CoV-2, including many broad-spectrum antivirals. One such antiviral, merimepodib (MMPD), has already being tested against hepatitis C in patients as well as against many emerging RNA viruses in cell culture, including Zika, Ebola, Lassa, Junin, and chikungunya viruses (1) . Early work suggests that IMPDH may directly interact with SARS-CoV-2 nsp13, perhaps indicating that drugs targeting IMPDH such as MMPD might have an impact on viral replication (5) . Our results show that MMPD can inhibit SARS-CoV-2 replication at low concentrations. Further work is needed to characterize the full mechanism behind MMPD inhibition of SARS-CoV-2 as well as its efficacy in animal models of corona virus infections. Merimepodib, an IMPDH inhibitor, suppresses replication of Zika virus and other emerging viral pathogens	./cache/cord-325432-geb4esu5.txt	./txt/cord-325432-geb4esu5.txt